 N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof |
| We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (... |
|
| Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents |
| OF THE INVENTION AND PREFERRED EMBODIMENTS In its broadest aspect, the present invention relates ... |
|
| Racemates of optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A diasteromic salt of i. a bicyclic imino-.alpha.-carboxylic ester of the formulae Ia ... |
|
| Disubstituted proline derivatives |
| We claim: 1. A compound of the formula I ##STR15## in which R.sup.1 and R.sup.2 together represent ... |
|
| Carboxyalkyl dipeptides and anti-hypertensive use thereof |
| We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable ... |
|
| Optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A compound of the formulae Ia or Ib essentially free of its racemate, and salts of ... |
|
| 5-HT.sub.3 receptor antagonists for treatment of cough and bronchoconstriction |
| I claim: 1. A method of treatment of cough and/or bronchoconstriction in mammals, which method ... |
|
| Therapeutic compositions with enhanced bioavailability |
| OF THE INVENTION This invention relates to compositions of a drug with a water soluble polymer ... |
|
|
Vaginal sponge delivery system
| Details |
Inventors: Myhling, John;
Assignee: Gynetech Laboratories, Ltd. (New York, NY)
Primary Examiner: Azpuru; Carlos
Assistant Examiner:
Attorney, Agent or Firm: Levisohn, Lerner, Berger and Langsam
A product for the administration of an active pharmaceutical agent via the vaginal canal comprising: (a) a sealed, air-tight package, enclosing therein; (b) a sponge impregnated with a liquid containing an effective amount of an active pharmaceutical agent, said liquid being present in an amount greater than that which is blocked within said sponge but less than the saturation value of said sponge such that when said sponge is inserted in the vaginal canal it will release liquid therefrom. |
|
DETAILED DESCRIPTION These and other objects of the invention are achieved in a product which broadly comprises (a) a sealed, air-tight package, enclosing therein (b) a sponge impregnated with the liquid containing an effective amount of an active pharmaceutical agent, the liquid being present in an amount greater than that which is blocked within said sponge, but less than the saturation value of the sponge so that when the sponge is implanted in the vaginal canal it will release liquid therefrom.
Thus, the present invention now provides a removable, premoistened vaginal sponge impregnated with a solution containing a carrier and an active pharmaceutical agent.
The sponge contains both an amount of solution that is tightly held by the sponge, i.
e.
blocked therein, and a freely releasable amount of solution that is released upon mechanical deflection, i.
e.
squeezing of the sponge.
As used in the specification and claims of this application, the terms "releasable" or "freely releasable" or "mechanically releasable" are used interchangeably and mean an amount of liquid that can be expelled from the sponge by simple compression or squeezing of the sponge.
The term "tightly bound" or "blocked" means an amount of liquid retained by the sponge even when compressed and which is only removable from the sponge by some type of non-mechanical means, such as evaporation.
The term "saturation value" means the maximum amount of liquid that can be held by the sponge.
A saturated sponge will release liquid immediately upon being squeezed.
According to one embodiment of the invention there is provided a vaginal device comprising a hermetically sealed air tight package enclosing therein a sponge impregnated with a liquid containing an active pharmaceutical agent, the amount of liquid being sufficient to provide a reservoir of the liquid while the sponge is in place in the vagina.
The sponge contains a mechanically releasable amount of liquid containing an active pharmaceutical agent and that releasable amount of liquid may contain or itself may comprise a prescribed unit dosage for a specific window of therapy or half-life drug metabolism
|
| Related patents |
|
|
Controlled release formulation
What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation in the form of an uncoated tablet from which upon ingestion ...
|
|
|
Formulations providing three distinct releases
We claim: 1. A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which ...
|
|
|
Floating sustained release therapeutic compositions
OF THE INVENTION According to the present invention, therapeutic dosage forms have now been discovered which are easy to prepare, provide sustained release of contained ...
|
|
|
Solid oral dosage forms of ifosfamide
OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 Ifosfamide capsule mass In accordance with the invention, the capsule mass is ...
|
|
|
[(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt thereof, or a stereochemically isomeric form thereof, wherein: X is O,...
|
|
|
Methods for treating dermatitis using descarboethoxyloratadine
OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects ...
|
|
|
Fat emulsions containing isocarbacyclin
What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable oil, phospholipid, water, and a pharmaceutically effective amount of at ...
|
|
|
Dermal pharmaceutical preparations
OF THE INVENTION The support which can be used in the present invention functions to retain a layer of a pressure-sensitive adhesive containing a drug and is selected ...
|
|
|
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the formula: ##STR20## wherein R.sub.1 represents lower-alkyl having 1 to 4 ...
|
|
|
2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use
We claim: 1. A compound of the formula I ##STR11## in which n denotes 1, 2, 3 or 4, R denotes (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.5 -C.sub.9)-...
|
|
|
Vasodialators 
